Future Uses of Elacestrant in Metastatic/Early-Stage Breast Cancer

News
Video

Data from the phase 3 EMERALD trial (NCT03778931) indicated that elacestrant (Orserdu) appeared to yield significant PFS benefit vs standard-of-care endocrine therapy in ER-positive/HER2-negative metastatic breast cancer, and warrants further investigation, according to Janice Lu, MD, PhD at the 2023 San Antonio Breast Cancer Symposium (SABCS).1

In a conversation with CancerNetwork®, Lu, professor and director of Breast Medical Oncology at Northwestern University Lurie Comprehensive Cancer Center, discussed the possible future for elacestrant as a monotherapy or in combination with other therapies in metastatic and early-stage breast cancer.

Transcript:

The subgroup analysis of elacestrant presented at the 2023 SABCS, in my opinion, is quite impressive. Elacestrant is now being investigated in several clinical trials alone or in combination with other therapies, both in metastatic and in early-stage breast cancer. There are 2 abstracts [that were] presented: One is the phase 1b/2 ELEVATE trial [NCT05563220],2 and the other one is the phase 1b/2 ELECTRA trial [NCT05386108].3

ELEVATE is an ongoing open-label umbrella study evaluating elacestrant in various combinations in the metastatic setting, [including] alpelisib [Piqray], everolimus [Afinitor], palbociclib [Ibrance], abemaciclib [Verzenio], or ribociclib [Kisqali]. The ELECTRA trial is a study of abemaciclib and elacestrant in patients with brain metastases. At my institution, the Northwestern University Lurie Comprehensive Cancer Center, [there is] a study using single-agent elacestrant vs elacestrant in combination of CDK 4/6 inhibitor with prior exposure to a different CDK. Other trials are in development that will potentially move elacestrant to the first-line space and possibly in the adjuvant setting as well.

References

  1. Bardia A, Bidard FC, Neven P, et al. Elacestrant vs standard-of-care in ER+/HER2- advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial​. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX. Poster PS17-02.
  2. Rugo H, Bardia A, Cortés J, et al. ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)​. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX. Poster PO2-05-04.
  3. Ibrahim N, Kim S, Lin N, et al. ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC). Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX. Poster PO2-05-05.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content